Glenmark Life Sciences Limited - Disclosure of Related Party Transactions for the half year ended 30th September 2024

(Amounts in Rs. Millions)

																			(Amounts in Rs. Millions)		
									i		ļ ,		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-								
							i '		1	1 '			corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only								
					1		Value of the	i		In case monies are due to either		once, during the reporting period when such transaction was undertaken.									
	Details of the party entering into the transaction		Details of the counterparty					related party	Remark on	Value of transaction	party as a result of the		In case any financial indebtedness is								
													incurred to make or giv	loans inter-							
						Type of related party	Details of other Related	transaction as	approval by		transaction		corporate deposits, a		Details of the loans, inter-corporate deposits, advances or investments						
Sr. No						transaction	Party Transactions	approved by	Audit	during the						l l					
					•	-	,	the audit	Committee	reporting			investments								
			Î		Relationship of the	1		committee	Committee	period	Opening	1	Nature of indebtedness		Nature (loan/ advance/				Purpose for which the funds		
				1				(Refer Note 6)				Closing balance				Interest	_	Secured/	will be utilised by the		
	Name	PAN	Name	PAN				(balance	_		Cost Tenu	e inter-corporate deposit/	Rate (%)	Tenure	unsecured	ultimate recipient of funds		
					listed entity								any other etc.)		investment				(end-usage)		
	-	-		+			-								1	1			(end-usage)		
1	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Inc., USA		Refer Note 1	Sale of goods or services		500		138.50	306.25	183.42									
<u> </u>	Gleriinark Elle Sciences Ellinteu	_	Gleffillark Filatifiaceuticals IIIc., OSA	+	Kelei Note 1	Purchase of goods or	+	300		136.30	300.23	103.42				1			-		
	I																				
2	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Ltd., India		Refer Note 1	services		225	-	68.42	-	-									
	1			1			1			1				1				1			
3	Glenmark Life Sciences Limited	1	Glenmark Pharmaceuticals Ltd., India	1	Refer Note 1	Sale of goods or services	1	10,000	-	3,751.98	2,843.14	3,918.49		I I		1	1	1			
4	Glenmark Life Sciences Limited		Aculife Healthcare Private Limited		Fellow Subsidiary	Sale of goods or services		2	_	0.39											
_	Glefilliark Elle Sciences Ellinted	-	Acume riedicicale i rivate cimited	1 -	i cilow Subsidiary	Purchase of goods or				0.33						1					
	I																				
- 5	Glenmark Life Sciences Limited		Viso Farmaceutica S.L.U.		Refer Note 1	services		35	-	16.78	-2.10	-19.40									
						Purchase of goods or															
6	Glenmark Life Sciences Limited		Glenmark Farmaceutica Ltda., Brazil		Refer Note 1	services		80	-	34.06	-26.39	-45.09									
							Reimbursement of Expenses														
_																					
/	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Inc., USA	1	Refer Note 1	Any other transaction	to Fellow Subsiidary	-	-	15.90	-	-									
							Reimbursement of Expenses														
8	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Europe Ltd., U.K.		Refer Note 1	Any other transaction	to Fellow Subsiidary	-	-	-	-0.38	-8.11									
					Managing Director &																
q	Glenmark Life Sciences Limited		Dr. Yasir Rawjee		CEO	Remuneration		_	_	52.19	_										
	Glerman Ene Selences Emiliea	_	Dir rush navjec	+	020	remaneration	†			52.25					-	 			 		
10	Glenmark Life Sciences Limited		Mr. Tushar Mistry		Chief Financial Officer	Remuneration		-	-	12.42	-	-									
					Company Secretary &																
- 11	Glenmark Life Sciences Limited		Mr. Rudalf Corriea		Compliance Officer	Remuneration				1.61											
11	Glerimark Life Sciences Limited	-	IVIT. RUdali Corriea	1 -	Compliance Officer	Kemuneration		_		1.01						 					
	1	1	1	1		ĺ	1			l		l		l I	1	1		1	1		
	1	1	1	1	Executive Director &	ĺ	1			l		l		l I	1	1		1			
	1	1	1	1	Head of the Technical	ĺ	1			l		l		l I	1	1		1	1		
12	Glenmark Life Sciences Limited	1	Mr. Vinod Naik	1	Operations	Remuneration	1	-	-	17.81	-	-		l I	1	1		1			
		1		1	1					1							1	1			
12	Glenmark Life Sciences Limited	1	Mrs. Manju Agarwal	1	Non-executive Director	Any other transaction	Sitting Fees			0.70		l		l I	1	1		1	1		
13	Glenmark Life Sciences Limited	-1	IVII S. IVIBIIJU ABBI WBI	+	inon-executive pirector	Any other transaction	ortung rees		-	0.70		<u> </u>		\vdash	+	 	1	1	-		
	1	1	1	1		ĺ	1			l		l		l I	1	1		1	1		
14	Glenmark Life Sciences Limited		Mr. T L Easwar	1	Non-executive Director	Any other transaction	Sitting Fees	-	-	0.50	-	-									
																		1			
15	Glenmark Life Sciences Limited	1	Mr.Kaushikbhai Patel	1	Non-executive Director	Any other transaction	Sitting Fees	_	-	0.90	-	-		l I	1	1		1	1		
		1 -		1		,				5.50				l	1	 	1	1	t		
1.0	Classical Life Salaman Limit of	1	Ma Viia durana Chah	1	Name annual de Director		Sitting Form			0.50	ĺ	l		I I		1	1	1			
16	Glenmark Life Sciences Limited	-	Mr.Vijaykumar Shah	4	Non-executive Director	Any other transaction	Sitting Fees	-	-	0.50	-	-		l				ļ			
- 1	1	1		1			1			l	ĺ	l		I I		1	1	1			
17	Glenmark Life Sciences Limited		Mr.Savan Godiawala*	Ш_	Non-executive Director	Any other transaction	Sitting Fees	-	-	0.40	-	-			<u> </u>	<u> </u>		L	<u> </u>		

Notes:

- 1 Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.
- 2 Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.
- 3 Share Based Payment Expenses pertaining to Key Managerial Personnel is not included.
- 4 Balances have been aggregated entity wise for all type of transactions and shown as net receivable/(payable)
- 5 RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
- 6 The value of the related party transaction denotes the amount approved by the Audit Committee for financial year 2024-25 except for Glenmark Pharmaceuticals Limited where the same was approved by the Audit Committee, Board of Directors, Shareholders of the Company for period October 23 to September 2024.
- 7 * Appointed with effect from 25/04/2024